I'm curious about the business strategy. Does Google intend to license out tools, partner, or consult for commercial partners?
I'm curious about the business strategy. Does Google intend to license out tools, partner, or consult for commercial partners?
The new AlphaFold server does not do everything the paper says AlphaFold 3 says it does. You cannot predict docking with the server! That is the main interest of pharma companies, 'does our medication bind to the target protein?'. From the FAQ: 'AlphaFold Server is a web-service that offers customized biomolecular structure prediction. It makes several newer AlphaFold3 capabilities available, including support for a wider range of molecule type' - that's not ALL AlphaFold3 capabilities. Isomorphic prints the money with those additional capabilities.
It's hilarious that Google says they don't allow this for safety reasons, pure OpenAI fluff. It's just money.
https://github.com/RosettaCommons/RoseTTAFold/blob/main/LICE...
But there's also:
https://files.ipd.uw.edu/pub/RoseTTAFold/Rosetta-DL_LICENSE....
Which is it?
I do agree that Google seems bad at commercialization, which is why I'm curious on what the strategy is.
It is hard to see them being paid consultants or effective partners for pharma companies, let alone developing drugs themselves.